Molecular mechanisms of sorafenib action in liver cancer cells

Cell Cycle

Volumn 11, Issue 15, 2012, Pages 2843-2855

  Cervello, Melchiorre ^a   Bachvarov, Dimcho ^b,c   Lampiasi, Nadia ^a   Cusimano, Antonella ^a   Azzolina, Antonina ^a   McCubrey, James A ^d   Montalto, Giuseppe ^a,e  

^a CNR   (Italy)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d EAST CAROLINA UNIVERSITY   (United States)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Acheron LARP6; Cell cycle; Dickkopf1; Global gene expression analysis; Harakiri; HCC; Microarray; Mini chromosome maintenance genes; Sorafenib; YAP1

Indexed keywords

SORAFENIB;

ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL CYCLE REGULATION; CELL METABOLISM; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING;

EID: 84864561983     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21193     Document Type: Article

References (63)

1. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963:13-20; PMID:12095924; http://dx.doi.org/10.1111/j.1749-6632.2002.tb04090.x.
2. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010; 78(Suppl 1):7-10; PMID:20616577; http://dx.doi.org/10.1159/000315223.
3. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48:1312-27; PMID:18821591; http://dx.doi.org/10. 1002/hep.22506.
4. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3:236-60; PMID:22470194.
5. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2:135-64; PMID:21411864.
6. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer.Oncotarget 2011; 2:122-34; PMID:21399234.
7. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 2007; 27:5499-513; PMID:17548474; http://dx.doi.org/10.1128/MCB.01080-06.
8. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 2011; 55:1041-8; PMID:21354226; http://dx.doi.org/10.1016/j.jhep.2011.01.047.
9. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, et al. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 2009; 220:214-21; PMID:19288493; http://dx.doi.org/10.1002/jcp.21753.
10. Cervello M, Giannitrapani L, Labbozzetta M, Notarbartolo M, D'Alessandro N, Lampiasi N, et al. Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann N Y Acad Sci 2004; 1028:432-9; PMID:15650268; http://dx.doi.org/10.1196/annals.1322.051.
11. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-61; PMID:15870716; http://dx.doi.org/10.1038/sj.bjc.6602584.
12. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-72; PMID:15613696; http://dx.doi.org/10.1200/JCO.2005.06.124.
13. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008; 99:1492-8; PMID:18477034; http://dx.doi.org/10.1111/j.1349-7006.2008.00837.x.
14. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24:6861-9; PMID:16007148; http://dx.doi.org/10.1038/sj.onc.1208841.
15. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280:35217-27; PMID:16109713; http://dx.doi.org/10.1074/jbc.M506551200.
16. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851-8; PMID:17178882; http://dx.doi.org/10.1158/0008-5472.CAN-06-1377.
17. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3:192-222; PMID:21422497.
18. Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett 2010; 478:165-70; PMID:20470863; http://dx.doi.org/10.1016/j.neulet.2010.05.009.
19. Noseda M, Karsan A. Notch and minichromosome maintenance (MCM) proteins: integration of two ancestral pathways in cell cycle control. Cell Cycle 2006; 5:2704-9; PMID:17172856; http://dx.doi.org/10.4161/cc.5.23.3515.
20. Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C, et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 2009; 162:1220-31; PMID:19447162; http://dx.doi.org/10.1016/ j.neuroscience.2009.05.019.
21. Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int 2011; 11:44; PMID:22206574; http://dx.doi.org/10.1186/1475-2867-11-44.
22. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009; 50:1861-70; PMID:19821497; http://dx.doi.org/10.1002/hep.23214.
23. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007; 67:9490-500; PMID:17909059; http://dx.doi.org/10.1158/0008-5472.CAN-07-0598.
24. Huber S, Oelsner M, Decker T, zum Büschenfelde CM, Wagner M, Lutzny G, et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011; 25:838-47; PMID:21293487; http://dx.doi.org/10.1038/leu.2011.2.
25. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget 2011; 2:239-44; PMID:21608150.
26. Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, et al. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2010; 70:9309-18; PMID:21062976; http://dx.doi.org/10.1158/0008-5472.CAN-10-1033.
27. Cai L, Fritz D, Stefanovic L, Stefanovic B. Binding of LARP6 to the conserved 5' stem-loop regulates translation of mRNAs encoding type I collagen. J Mol Biol 2010; 395:309-26; PMID:19917293; http://dx.doi.org/10.1016/j.jmb. 2009.11.020.
28. Cai L, Fritz D, Stefanovic L, Stefanovic B. Coming together: liver fibrosis, collagen mRNAs and the RNA binding protein. Expert Rev Gastroenterol Hepatol 2009; 3:1-3; PMID:19210106; http://dx.doi.org/10.1586/17474124.3.1.1.
29. Shao R, Scully SJ Jr., Yan W, Bentley B, Mueller J, Brown C, et al. The novel lupus antigen related protein acheron enhances the development of human breast cancer. Int J Cancer 2012; 130:544-54; PMID:21387291; http://dx.doi.org/10.1002/ijc.26015.
30. Sun R, Chen W, Zhao X, Li T, Song Q. Acheron regulates vascular endothelial proliferation and angiogenesis together with Id1 during wound healing. Cell Biochem Funct 2011; 29:636-40; PMID:22139627; http://dx.doi.org/ 10.1002/cbf.1799.
31. Inohara N, Ding L, Chen S, Núñez G. Harakiri: A novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 1997; 16:1686-94; PMID:9130713; http://dx.doi.org/10.1093/emboj/16.7.1686.
32. Gurzov EN, Ortis F, Cunha DA, Gosset G, Li M, Cardozo AK, et al. Signaling by IL-1beta+IFN-gamma and ER stress converge on DP5/Hrk activation: a novel mechanism for pancreatic beta-cell apoptosis. Cell Death Differ 2009; 16:1539-50; PMID:19629134; http://dx.doi.org/10.1038/cdd.2009.99.
33. Nakamura M, Shimada K, Konishi N. The role of HRK gene in human cancer. Oncogene 2008; 27(Suppl 1):S105-13; PMID:19641496; http://dx.doi.org/10.1038/ onc.2009.48.
34. Ma C, Ying C, Yuan Z, Song B, Li D, Liu Y, et al. dp5/HRK is a c-Jun target gene and required for apoptosis induced by potassium deprivation in cerebellar granule neurons. J Biol Chem 2007; 282:30901-9; PMID:17428807; http://dx.doi.org/10.1074/jbc.M608694200.
35. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115:4576-85; PMID:19551889; http://dx.doi.org/10.1002/cncr.24495.
36. Yee KS, O'Neill E. YAP1 - friend and foe. Cell Cycle 2010; 9:1447-8; PMID:20372091; http://dx.doi.org/10.4161/cc.9.8.11480.
37. Bertini E, Oka T, Sudol M, Strano S, Blandino G. YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 2009; 8:49-57; PMID:19106601; http://dx.doi.org/10.4161/cc.8.1.7259.
38. Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999; 274:19465-72; PMID:10383463; http://dx.doi.org/10.1074/jbc.274.27.19465.
39. Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 2009; 50:948-57; PMID:19303159; http://dx.doi.org/10.1016/j.jhep.2008.11.020.
40. Menezes ME, Devine DJ, Shevde LA, Samant RS. Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 2012; 130:1477-83; PMID:21953410; http://dx.doi.org/10.1002/ijc.26449.
41. Sato N, Yamabuki T, Takano A, Koinuma J, Aragaki M, Masuda K, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010; 70:5326-36; PMID:20551066; http://dx.doi.org/10.1158/0008-5472.CAN-09- 3879.
42. Makino T, Yamasaki M, Takemasa I, Takeno A, Nakamura Y, Miyata H, et al. Dickkopf-1 expression as a marker for predicting clinical outcome in esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16:2058-64; PMID:19408050; http://dx.doi.org/10.1245/s10434-009-0476-7.
43. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007; 67:2517-25; PMID:17363569; http://dx.doi.org/10. 1158/0008-5472.CAN-06-3369.
44. Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int 2011; 31:1494-504; PMID:21955977; http://dx.doi.org/10.1111/j.1478-3231.2011.02597.x.
45. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/ NEJMoa0708857.
46. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15:167-70; PMID:19249675; http://dx.doi.org/10.1016/j.ccr.2009.02.007.
47. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005; 42:358-64; PMID:15710218; http://dx.doi.org/10.1016/ j.jhep.2004.11.020.
48. Miyoshi A, Kitajima Y, Ide T, Ohtaka K, Nagasawa H, Uto Y, et al. Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int J Oncol 2006; 29:1533-9; PMID:17088993.
49. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22:1178-82; PMID:17559361; http://dx.doi.org/10.1111/j.1440-1746.2007.04997.x.
50. Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 2002; 80:703-14; PMID:12436347; http://dx.doi.org/10.1007/s00109-002-0380-0.
51. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15:167-70; PMID:19249675; http://dx.doi.org/10.1016/j.ccr.2009.02.007.
52. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027.
53. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9; PMID:19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021.
54. Yadav A, Kumar B, Teknos TN, Kumar P. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 2011; 10:1241-51; PMID:21551262; http://dx.doi.org/10.1158/1535-7163.MCT-11-0004.
55. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154-60; PMID:21081728; http://dx.doi.org/10.1001/jama.2010.1672.
56. National Cancer Institute clinical trials Web page. Phase III randomized study of sorafenib tosylate with versus without doxorubicin hydrochloride in patients with locally advanced or metastatic hepatocellular carcinoma. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=659348&version= HealthProfessional&protocolsearchid=7262229
57. Cervello M, Notarbartolo M, Landino M, Cusimano A, Virruso L, Montalto G, et al. Downregulation of wild-type beta-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? Eur J Cancer 2001; 37:512-9; PMID:11267862; http://dx.doi.org/10.1016/S0959-8049(00)00421-4.
58. Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, D'Alessandro N, et al. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 2010; 9:1399-410; PMID:20305374; http://dx.doi.org/10.4161/cc.9.7.11254.
59. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55; PMID:6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4.
60. Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, et al. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol Pharmacol 2009; 76:290-300; PMID:19461054; http://dx.doi.org/10.1124/mol.109.055418.
61. Bachvarov D, Bachvarova M, Koumangaye R, Klein J, Pesquero JB, Neau E, et al. Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes. Biol Chem 2006; 387:15-22; PMID:16497160; http://dx.doi.org/10.1515/BC.2006.004.
62. L'Espérance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 2006; 29:5-24; PMID:16773180.
63. Cervello M, Bachvarov D, Cusimano A, Sardina F, Azzolina A, Lampiasi N, et al. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. OMICS 2011; 15:383-92; PMID:21410330; http://dx.doi.org/10.1089/omi.2010.0092.